Update on the pathology and genetics of exocrine pancreatic tumors with ductal phenotype: Precursor lesions and new tumor entities

Digestive Diseases

Volumn 19, Issue 1, 2001, Pages 15-23

  Luttges J ^a   Klöppel, Günter ^a  

^a UNIVERSITY OF KIEL   (Germany)

Author keywords

Pancreactic intraepithelial neoplasia; Pancreatic neoplasms, phenotype; Standardization, pancreatic duct lesions; Tumor precursors

Indexed keywords

CANCER GRADING; IMMUNOHISTOCHEMISTRY; INVASIVE CARCINOMA; MEDICAL GENETICS; MEDULLARY CARCINOMA; MUCINOUS CARCINOMA; PANCREAS ADENOCARCINOMA; PANCREAS DUCT; PANCREAS TUMOR; PAPILLOMA; PATHOLOGY; PHENOTYPE; PRIORITY JOURNAL; REVIEW; STANDARDIZATION; TUMOR CLASSIFICATION; UNDIFFERENTIATED CARCINOMA;

CARCINOMA IN SITU; CARCINOMA, MEDULLARY; CARCINOMA, PANCREATIC DUCTAL; CYSTADENOCARCINOMA, MUCINOUS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; NEOPLASM INVASIVENESS; NEOPLASM STAGING; PANCREATIC NEOPLASMS; PEDIGREE; PHENOTYPE;

EID: 0034980577     PISSN: 02572753     EISSN: None     Source Type: Journal    
DOI: 10.1159/000050649     Document Type: Review

References (83)

1. Ductal adenocarcinoma of the pancreas
2. Genetics of pancreatic cancer: From genes to families
3. Tumors of the exocrine pancreas
4. Intraductal proliferation in the pancreas and its relationship to human and experimental carcinogenesis
5. Experimental evidence for the origin of ductal-type adenocarcinoma from the islets of Langerhans
6. Pancreatic duct hyperplasia and cancer
7. Relation of pancreatic duct hyperplasia to carcinoma
8. Morphological lesions associated with human primary invasive nonendocrine pancreas cancer
9. Histogenesis of pancreatic carcinomas: A study based on 248 cases
10. Progression of pancreatic intraductal neoplasias to infiltrating adenocarcinoma of the pancreas
11. Progression of atypical ductal hyperplasia/carcinoma in situ of the pancreas to invasive adenocarcinoma
12. Cancer surveillance of patients from familial pancreatic cancer kindreds
13. Early diagnosis and treatment of pancreatic dysplasia in patients with a family history of pancreatic cancer
14. Pancreatic intraepithelial neoplasia: A new nomenclature and classification system for pancreatic duct lesions
15. Precancerous conditions of pancreatic carcinoma
16. Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes
17. Ki-ras oncogene activation in preinvasive pancreatic cancer
18. The role of ras mutation in pancreatic cancer, precancerous lesions, and chronic pancreatitis
19. Detection of point mutations in the Kirsten-ras oncogene provides evidence for the multicentricity of pancreatic carcinoma
20. p16 and K-ras gene mutations in the intraductal precursors of human pancreatic adenocarcinoma
21. Determination of pancreatic ductal carcinoma histogenesis by analysis of mucous quality and K-ras mutation
22. The K-ras mutation pattern in pancreatic ductal adenocarcinoma is usually identical to that in associated normal, hyperplastic and metaplastic duct epithelium
23. Duct changes and K-ras mutations in the disease-free pancreas: Analysis of type, age relation and spatial distribution
24. Genetic progression and divergence in pancreatic carcinoma
25. Molecular analysis of microdissected tumors and preneoplastic intraductal lesions in pancreatic carcinoma
26. Allelic loss is often the first hit in the biallelic inactivation of the p53 and DPC4 genes during pancreatic carcinogenesis
27. DPC4, a candidate tumor suppressor gene at human chromosome 18q21.1
28. Abrogation of the Rb/p16 tumor-suppressive pathway in virtually all pancreatic carcinomas
29. Genetic progression in the pancreatic ducts
30. Detection of K-ras mutations in the stool of patients with pancreatic adenocarcinoma and pancreatic ductal hyperplasia
31. Frequent c-Ki-ras oncogene activation in mucous cell hyperplasias of pancreas suffering from chronic inflammation
32. Analysis of K-ras gene mutation in hyperplastic duct cells of the pancreas without pancreatic disease
33. Immunohistochemical evaluation of HER-2/neuexpression in pancreatic adenocarcinoma and pancreatic intraepithelial neoplasms
34. BRCA2 is inactivated late in the development of pancreatic intraepithelial neoplasia: Evidence and implications
35. Expression of the tumor suppressor gene maspin in human pancreatic cancers
36. Pancreatic, non-endocrine tumours
37. Malignant fibrous histiocytoma (giant cell type) of the pancreas: A distinctive variant of osteoclast-type giant cell tumor of the pancreas
38. Malignant fibrous histiocytoma of the pancreas: A case report with genetic analysis
39. KRAS oncogene mutations suggest a common histogenetic origin for pleomorphic giant cell tumor of the pancreas, osteoclastoma of the pancreas, and pancreatic duct adenocarcinoma
40. Undifferentiated carcinoma with osteoclast-like giant cells of the pancreas and periampullary region
41. Undifferentiated carcinoma of the pancreas: Analysis of intermediate filament profile and Ki-ras mutations provides evidence of a ductal origin
42. Origin of giant cells in osteoclast-like giant cell tumors of the pancreas
43. K-ras oncogene mutations in osteoclast-like giant cell tumors of the pancreas and liver: Genetic evidence to support origin from the duct epithelium
44. Immunohistochemical and molecular analysis of giant cell carcinoma of the pancreas: A report of three cases
45. Mucinous cystic neoplasms of the pancreas
46. Colloid (mucinous noncystic) carcinoma of the pancreas
47. The immunohistochemical mucin expression pattern distinguishes different types of intraductal papillary mucinous neoplasms of the pancreas and determines their relationship to mucinous noncystic carcinoma and ductal adenocarcinoma
48. Intraductal papillarymucinous tumours represent a distinct group of pancreatic neoplasms: An investigation of tumour cell differentiation and K-ras, p53, and c-erbB-2 abnormalities in 26 patients
49. Dpc-4 protein is expressed in virtually all human intraductal papillary mucinous neoplasms of the pancreas: Comparison with conventional ductal adenocarcinomas
50. Intraductal mucin-hypersecreting neoplasms of the pancreas: A clinicopathologic study of eight patients
51. Intraductal papillary mucinous tumours of the pancreas: Clinical and therapeutic issues in 32 patients
52. Intraductal papillary-mucinous tumors of the pancreas: Clinicopathologic features, outcome, and nomenclature
53. Characteristics and treatment of mucin-producing tumor of the pancreas
54. Pancreatic tumors with cystic dilatation of the ducts: Intraductal papillary mucinous neoplasms and intraductal oncocytic papillary neoplasms
55. Clinicopathologic view of intraductal papillary-mucinous tumor of the pancreas
56. Invasive carcinoma derived from intraductal papillary-mucinous carcinoma of the pancreas: Clinicopathologic and immunohistochemical study of 8 cases
57. Intraductal papillary mucinous tumors of the pancreas confined to secondary ducts show less aggressive pathologic features as compared with those involving the main pancreatic duct
58. Intraductal papillary-mucinous neoplasms of the pancreas
59. Preoperative diagnosis of intraductal papillary-mucinous tumors of the pancreas with attention to telomerase activity
60. K-ras gene mutations and loss of heterozygosity at the p53 gene locus relative to histological characteristics of mucin-producing tumors of the pancreas
61. Genetic progression and heterogeneity in intraductal papillary-mucinous neoplasms of the pancreas
62. MUC2 gene expression is found in noninvasive tumors but not in invasive tumors of the pancreas and liver: Its close relationship with prognosis of the patients
63. MUC-1 mucin expression in invasive areas of intraductal papillary mucinous tumors of the pancreas
64. Expression of MUC apomucins in normal pancreas and pancreatic tumours
65. Intraductal oncocytic papillary neoplasms of the pancreas
66. Mucinous cystic neoplasms of the pancreas with overt and latent malignancy (cystadenocarcinoma and cystadenoma): A clinicopathologic study of 41 cases
67. Mucinous cystic tumors of the pancreas: Clinicopathological features, prognosis and relationship to other mucinous cystic tumors
68. Pathologic examination accurately predicts prognosis in mucinous cystic neoplasms of the pancreas
69. Sequential accumulation of K-ras mutations and p53 overexpression in the progression of pancreatic mucinous cystic neoplasms to malignancy
70. Higher frequency of DPC4/Smad4 alterations in pancreatic cancer cell lines than in primary pancreatic adenocarcinomas
71. Dpc4 protein in mucinous cystic neoplasms of the pancreas: Frequent loss of expression in invasive carcinomas suggests a role in genetic progression
72. Pancreatic adenocarcinomas with DNA replication errors (RER+) are associated with wild-type K-ras and characteristic histopathology: Poor differentiation, a syncytial growth pattern, and pushing borders suggest RER+
73. Genetic, immunohistochemical, and clinical features of medullary carcinoma of the pancreas: A newly described and characterized entity
74. Hereditary pancreatitis and the risk of pancreatic cancer
75. Familial pancreatic cancer: A review
76. Familial pancreatic adenocarcinoma: Association with diabetes and early molecular diagnosis
77. Clear cell carcinoma of the pancreas: An adenocarcinoma with ductal phenotype
78. Foamy gland pattern of pancreatic ductal adenocarcinoma: A deceptively benign-appearing variant
79. Mixed ductal-endocrine carcinoma of the pancreas presenting as gastrinoma with Zollinger-Ellison syndrome: An autopsy case with a 24-year survival period
80. Mixed exocrine-endocrine tumors of the pancreas